Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Lymphoma, B-Cell
  • Rituximab

abstract

  • Obinutuzumab demonstrated a higher ORR without appreciable differences in safety compared with rituximab. However, the clinical benefit of obinutuzumab in this setting remains unclear and should be evaluated within phase III trials.

publication date

  • October 20, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5087315

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.59.2139

PubMed ID

  • 26282650

Additional Document Info

start page

  • 3467

end page

  • 74

volume

  • 33

number

  • 30